- The abstract drop for the European Society for Medical Oncology (ESMO) will launch in less than six hours. The conference will take place September 8-12 in Madrid. Presentations to watch:
- AstraZeneca (NYSE:AZN): Top-line data from Phase 3 FLAURA study assessing Tagrisso (osimertinib) in EGFR+ NSCLC patients. Primary endpoint: PFS.
- Data from Phase 3 PACIFIC study of durvalumab in NSCLC.
- Clovis Oncology (NASDAQ:CLVS): Data from Phase 3 ARIEL3 study of Rubraca (rucaparib) in advanced ovarian cancer.
- Curis (NASDAQ:CRIS): Phase 1 data on CA-170.
- Exelixis (NASDAQ:EXEL): Data on Phase 2 CABOSUN study comparing cabozantinib to SUTENT (sunitinib) in treatment-naive RCC. Phase 1b data on cabozantinib + Yervoy + Opdivo in genitourinary cancers.
- Eli Lilly (NYSE:LLY): Data from Phase 3 MONARCH 3 study of abemaciclib in breast cancer and data from Phase 3 RANGE study of ramucirumab in urothelial cancer.
- Merck (NYSE:MRK)/Incyte (NASDAQ:INCY): Data from Phase 1/2 ECHO-202 study of pembrolizumab/epacadostat combo in selected cancers, specifically the melanoma cohort.
- Kite Pharma (NASDAQ:KITE): Updated data from ZUMA-3 and ZUMA-4.
- TESARO (NASDAQ:TSRO): Data from Phase 1/2 TOPACIO study of niraparib + Keytruda (pembrolizumab) in TNBC.
- Source: Bloomberg
- Now read: How Gilead Paid Billion For Million In Revenue And Thinks To Make A Profit
Original article